2. Gene
  3. BCL2 - BCL2, apoptosis regulator Gene

BCL2 - BCL2, apoptosis regulator Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：BCL2 ，细胞凋亡调节因子

种属: Rattus norvegicus

同用名: Bcl-2

基因 ID: 24224 | 基因类型: protein coding

关于 BCL2

Biased expression in Spleen (RPKM 83.4), Thymus (RPKM 72.9) and 9 other tissues.

功能概要

该基因编码的蛋白可启动 BH 域绑定活动。参与多个过程，包括对肽的反应；对含嘌呤化合物的反应；和对维生素的反应。位于胞质溶胶中；线粒体嵴；和细胞质的核周区。用于研究多种疾病，包括脑缺血（多种）；晚期肾脏疾病;胃溃疡;肠道疾病（多种）；和癫痫持续状态。几种疾病的生物标志物，包括腹型肥胖-代谢综合征 1；脑部疾病（多种）；高血压（多发性）；内在性心肌病（多发性）；和神经退行性疾病（多种）。该基因的人类直系同源物与多种疾病有关，包括癌（多种）；血液系统癌症（多发性）；颅内动脉瘤;前列腺癌;和膀胱癌。与人 BCL2 同源（BCL2 细胞凋亡调节剂）。 [由基因组资源联盟提供，2022 年 4 月]

Enables BH domain binding activity. Involved in several processes, including response to peptide; response to purine-containing compound; and response to vitamin. Located in cytosol; mitochondrial crista; and perinuclear region of cytoplasm. Used to study several diseases, including brain ischemia (multiple); end stage renal disease; gastric ulcer; intestinal disease (multiple); and status epilepticus. Biomarker of several diseases, including abdominal obesity-metabolic syndrome 1; brain disease (multiple); hypertension (multiple); intrinsic cardiomyopathy (multiple); and neurodegenerative disease (multiple). Human ortholog(s) of this gene implicated in several diseases, including carcinoma (multiple); hematologic Cancer (multiple); intracranial aneurysm; prostate cancer; and urinary bladder Cancer. Orthologous to human BCL2 (BCL2 Apoptosis regulator). [provided by Alliance of Genome Resources, Apr 2022]

BCL2 基因产物(1)

mRNA Protein Name
NM_016993.2 NP_058689.2 apoptosis regulator Bcl-2
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables BH domain binding IPI
IPI: 通过物理相互作用推断
9356461 RGD
enables protein binding IPI
IPI: 通过物理相互作用推断
15004018 RGD
enables protein-containing complex binding IPI
IPI: 通过物理相互作用推断
9356461 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in cellular response to fluoride IEP
IEP: 通过表达模式推断
16388103 RGD
involved in cellular response to glucose stimulus IEP
IEP: 通过表达模式推断
21474815 RGD
involved in cellular response to hydrogen peroxide IEP
IEP: 通过表达模式推断
16157298 RGD
involved in cellular response to hypoxia IEP
IEP: 通过表达模式推断
20669351 RGD
involved in cellular response to organic cyclic compound IEP
IEP: 通过表达模式推断
19574995 RGD
involved in cerebral cortex development IEP
IEP: 通过表达模式推断
9813151 RGD
involved in glial cell apoptotic process IEP
IEP: 通过表达模式推断
18931364 RGD
involved in liver regeneration IEP
IEP: 通过表达模式推断
21503946 RGD
involved in negative regulation of apoptotic process IDA
IDA: 通过直接分析推断
11879647 RGD
involved in negative regulation of apoptotic process IMP
IMP: 通过突变表型推断
15004018 RGD
involved in negative regulation of cardiac muscle cell apoptotic process IMP
IMP: 通过突变表型推断
26692938 RGD
involved in oligodendrocyte differentiation IEP
IEP: 通过表达模式推断
12787069 RGD
involved in ovarian follicle development IEP
IEP: 通过表达模式推断
17570453 RGD
involved in response to L-ascorbic acid IEP
IEP: 通过表达模式推断
18758938 RGD
involved in response to aluminum ion IEP
IEP: 通过表达模式推断
17967740 RGD
involved in response to amyloid-beta IEP
IEP: 通过表达模式推断
18374914 RGD
involved in response to cAMP IEP
IEP: 通过表达模式推断
18086876 RGD
involved in response to caffeine IEP
IEP: 通过表达模式推断
17236787 RGD
involved in response to copper ion IEP
IEP: 通过表达模式推断
18289470 RGD
involved in response to corticosterone IEP
IEP: 通过表达模式推断
17562391 RGD
involved in response to cytokine IEP
IEP: 通过表达模式推断
18832793 RGD
involved in response to electrical stimulus IEP
IEP: 通过表达模式推断
17700647 RGD
involved in response to erythropoietin IEP
IEP: 通过表达模式推断
26261574 RGD
involved in response to estrogen IEP
IEP: 通过表达模式推断
16084662 RGD
involved in response to ethanol IDA
IDA: 通过直接分析推断
18259862 RGD
involved in response to ethanol IEP
IEP: 通过表达模式推断
15469889 RGD
involved in response to folic acid IEP
IEP: 通过表达模式推断
18156304 RGD
involved in response to hypoxia IEP
IEP: 通过表达模式推断
16445580 RGD
involved in response to insulin IEP
IEP: 通过表达模式推断
18758938 RGD
involved in response to ischemia IEP
IEP: 通过表达模式推断
31583047 RGD
involved in response to monosaccharide IEP
IEP: 通过表达模式推断
26261574 RGD
involved in response to nicotine IEP
IEP: 通过表达模式推断
15332118 RGD
involved in response to nutrient IEP
IEP: 通过表达模式推断
16216918 RGD
involved in response to organic cyclic compound IEP
IEP: 通过表达模式推断
18384965 RGD
involved in response to peptide hormone IEP
IEP: 通过表达模式推断
15686664 RGD
involved in response to phenylpropanoid IEP
IEP: 通过表达模式推断
22700048 RGD
involved in response to vitamin E IEP
IEP: 通过表达模式推断
26261574 RGD
involved in response to xenobiotic stimulus IEP
IEP: 通过表达模式推断
18284815 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in mitochondrial crista IDA
IDA: 通过直接分析推断
9731187 RGD
located in perinuclear region of cytoplasm IDA
IDA: 通过直接分析推断
11299004 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

BCL2 蛋白结构

bcl-2

bcl-2: TIGR00865 (10 - 235)

  • 0
  • 100
  • 200
  • 236 a.a.
蛋白主名 其他名称

apoptosis regulator Bcl-2

B cell lymphoma 2 associated oncogene

B-cell CLL/lymphoma 2

B-cell leukemia/lymphoma 2

Bcl-2alpha

Bcl2-like protein

相关产品

Approval
生物活性分子 (10)
目录号 产品名 作用方式
纯度 是否罕见病
HY-15531 Venetoclax 99.95% 是
HY-B0011 Docetaxel 99.94% 否
HY-B0318 Metronidazole 99.92% 是
HY-13407 Gossypol Antagonist 99.67% 是
HY-B0011A Docetaxel Trihydrate 99.92% 否
HY-17510 Gossypol (acetic acid) Inhibitor 99.75% 是
HY-B0766 Bicyclol 99.91% 否
HY-118874 Oblimersen / 否
HY-B0318A Metronidazole hydrochloride / 否
HY-B0011R Docetaxel (Standard) / 否
Clinical Phase
生物活性分子 (20)
目录号 产品名 作用方式
纯度 Phase
HY-105930 Lobaplatin ≥98.0% Phase 4
HY-10087 Navitoclax Inhibitor 99.97% Phase 3
HY-10969 Obatoclax Mesylate 99.85% Phase 3
HY-15464A (R)-(-)-Gossypol acetic acid 98.93% Phase 3
HY-N0867 13-Oxyingenol-13-dodecanoate 99.37% Phase 3
HY-10969A Obatoclax ≥99.0% Phase 3
HY-50868 Bafetinib 99.77% Phase 2
HY-109185 Pelcitoclax 99.70% Phase 2
HY-129179 Lisaftoclax Inhibitor 99.28% Phase 2
HY-N0068 Solasodine 99.54% Phase 2
HY-15464 (R)-(-)-Gossypol 98.82% Phase 2
HY-138697 S65487 99.91% Phase 2
HY-138697B S65487 hydrochloride 99.67% Phase 2
HY-123823 Nitroaspirin / Phase 2
HY-15464D (S)-Gossypol (acetic acid) Inhibitor 98.39% Phase 2
HY-138697A S65487 sulfate 98.08% Phase 2
HY-13559 Atiprimod / Phase 2
HY-117288 S55746 Inhibitor 99.89% Phase 1
HY-109184 Murizatoclax Inhibitor 98.85% Phase 1
HY-117288A S55746 hydrochloride Inhibitor 99.66% Phase 1
Pre-clinical Phase
生物活性分子 (235)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-50907 ABT-737 99.96% 否
HY-107738 Guggulsterone 99.95% 否
HY-130604 DT2216 99.97% 否
HY-N2342 Procyanidin C1 Inducer 99.79% 否
HY-N0292 Oleuropein 99.05% 否
HY-N0674 Dehydrocorydaline 99.77% 否
HY-126477 NNK 99.98% 否
HY-N0087 Gambogic Acid 98.79% 否
HY-N0361 Dihydrocapsaicin 99.93% 否
HY-112416 AZD4320 Inhibitor 99.68% 否
HY-18628 UMI-77 Inhibitor 99.66% 否
HY-148026 Sonrotoclax Inhibitor 99.61% 否
HY-125877 PROTAC Mcl1 degrader-1 Inhibitor 98.13% 否
HY-147081 AS 1411 Inhibitor / 否
HY-118119 CAY10526 Inhibitor 99.40% 否
HY-126741 Azadirachtin 99.06% 否
HY-N3584 Paris saponin VII 99.96% 否
HY-125876 PROTAC Bcl2 degrader-1 Inhibitor 99.80% 否
HY-124284 Hexamethylene bisacetamide 99.56% 否
HY-15531S Venetoclax-d8 99.76% 否
HY-N0265 Asperosaponin VI Inhibitor 98.91% 否
HY-N0674A Dehydrocorydaline chloride 99.72% 否
HY-103243 TCPOBOP Inhibitor 98.67% 否
HY-N2897 Dihydrokaempferol 99.88% 否
HY-12020 TW-37 Inhibitor 99.27% 否
HY-33350 Clofilium tosylate 99.84% 否
HY-139309 PROTAC Bcl-xL degrader-2 Inhibitor 98.16% 否
HY-N0674B Dehydrocorydaline (hydroxyl) 99.52% 否
HY-15191 Sabutoclax Inhibitor 99.80% 否
HY-133557 XZ739 99.06% 否
HY-120882 BM-1197 Inhibitor 99.48% 否
HY-138832 BM-1244 Inhibitor 99.85% 否
HY-12011 HA14-1 Inhibitor ≥98.0% 否
HY-N3001 Isolinderalactone Inhibitor 98.79% 否
HY-N6850 Calenduloside E 99.07% 否
HY-P1889 Bim BH3, Peptide IV 99.35% 否
HY-16014 A-385358 Inhibitor 98.19% 否
HY-129681 MCL-1/BCL-2-IN-1 Inhibitor 99.86% 否
HY-10087S Navitoclax-d8 Inhibitor 99.71% 否
HY-157176 BAX-IN-1 Inhibitor ≥98.0% 否
HY-161100 BDM19 Inducer 98.09% 否
HY-N1440 Koumine Activator 99.97% 否
HY-N7930 Crenulatin ≥99.0% 否
HY-142209 ABBV-167 Inhibitor 97.33% 否
HY-100383 BH3I-1 ≥98.0% 否
HY-132307 Mcl-1 inhibitor 6 98.40% 否
HY-119931 2-Hydroxychalcone 98.80% 否
HY-129700 MCL-1/BCL-2-IN-2 Inhibitor 99.12% 否
HY-156278 FB49 Inhibitor 99.76% 否
HY-N1157 Thevetiaflavone ≥98.0% 否
HY-N6690 Destruxin B 99.86% 否
HY-P1527 Bim BH3 99.80% 否
HY-113471A (S)-(-)-Perillic acid ≥95.0% 否
HY-118874A Oblimersen sodium Inhibitor 98.09% 否
HY-161254 ATPase-IN-3 99.89% 否
HY-169925 BM-962 Inhibitor 99.10% 否
HY-B0011S Docetaxel-d9 ≥98.0% 否
HY-N4238 Dehydrocorydaline nitrate 99.90% 否
HY-RS01415 BCL2 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-109617 4-(4-Fluorophenyl)benzoic acid 99.01% 否
HY-111329 JGB1741 99.05% 否
HY-119833 Rubone Modulator 99.1% 否
HY-129179B (Rac)-Lisaftoclax Inhibitor 98.22% 否
HY-13408 (+)-Apogossypol Inhibitor / 否
HY-160921 Capeserod Agonist 98.66% 否
HY-161276 BFC1108 Inducer 98.11% 否
HY-161410 WH244 Degrader / 否
HY-N0307 Ciwujianoside B Inhibitor 99.00% 否
HY-N2416 Taccalonolide A 99.29% 否
HY-P2343 BH3 hydrochloride Activator 98.02% 否
HY-RS01431 BCL2L13 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-15191B (S)-Sabutoclax Inhibitor 98.03% 否
HY-114310 VDR agonist 1 / 否
HY-128360 dMCL1-2 Inhibitor / 否
HY-131247 Bcl-2-IN-2 Inhibitor / 否
HY-135273 A-1211212 / 否
HY-155188 NWP-0476 Inhibitor / 否
HY-100762 Mcl1-IN-11 Inhibitor / 否
HY-100763 Mcl1-IN-12 Inhibitor / 否
HY-146097 RMS5 / 否
HY-149918 Antiproliferative agent-23 / 否
HY-156620 Lacutoclax Inhibitor / 否
HY-19551 Apogossypolone / 否
HY-B1559 Allethrin Inducer 98.04% 否
HY-10087A1 Navitoclax dihydrochloride Inhibitor / 否
HY-101083 BDA-366 Antagonist / 否
HY-101999 EM20-25 / 否
HY-115974 GRPR antagonist-1 / 否
HY-118925 Holothurin A Inhibitor / 否
HY-121934 BH3I-2' / 否
HY-123020 CYD-2-88 Antagonist / 否
HY-123034 CDKI-83 / 否
HY-123244 YC137 / 否
HY-124122 BPTQ / 否
HY-125191 BRD1991 Inhibitor / 否
HY-127130 Spicamycin / 否
HY-129701 MCL-1/BCL-2-IN-3 Inhibitor 99.22% 否
HY-129702 MCL-1/BCL-2-IN-4 Inhibitor / 否
HY-131188 PROTAC Bcl-xL degrader-1 Inhibitor / 否
HY-131405 β-Eleostearic acid Inhibitor / 否
HY-133772 Venetoclax N-oxide / 否
HY-13659 KRN5500 / 否
HY-13846 BM-1074 / 否
HY-143235 BRD4 Inhibitor-15 / 否
HY-143872 Bcl-2-IN-4 Inhibitor / 否
HY-143873 Bcl-2-IN-5 Inhibitor / 否
HY-144428 Bcl-2/Mcl-1-IN-2 Inhibitor / 否
HY-144430 Bcl-2/Mcl-1-IN-1 Inhibitor / 否
HY-144431 Bcl-2/Mcl-1-IN-3 Inhibitor / 否
HY-144778 IDO1/TDO-IN-1 / 否
HY-144791 Bcl-2-IN-6 / 否
HY-144792 Bcl-2-IN-7 / 否
HY-145288 Antitumor agent-36 / 否
HY-145289 Antitumor agent-37 / 否
HY-146095 p53 Activator 2 / 否
HY-146253 CDK1/2/4-IN-1 / 否
HY-146444 Anticancer agent 56 / 否
HY-146471 EGFR-IN-51 / 否
HY-146472 EGFR-IN-52 / 否
HY-146817 Tubulin polymerization-IN-11 / 否
HY-147504 Anticancer agent 63 / 否
HY-147826 EGFR-IN-60 / 否
HY-147906 Anticancer agent 71 / 否
HY-147928 Apoptotic agent-2 / 否
HY-147929 Apoptotic agent-3 / 否
HY-149009 Bcl-2-IN-9 / 否
HY-149024 VEGFR-2-IN-23 / 否
HY-149436 CDK2/Bcl2-IN-1 Inhibitor / 否
HY-149622 Bcl-2-IN-12 Inhibitor / 否
HY-149623 Bcl-2-IN-13 Inhibitor / 否
HY-149624 Bcl-2-IN-14 Inhibitor / 否
HY-149625 Bcl-2-IN-15 Inhibitor / 否
HY-149681 Beclin1-Bcl-2 interaction inhibitor 1 Inhibitor / 否
HY-150540 Bcl-2-IN-10 / 否
HY-150596 CT1-3 / 否
HY-151428 Antitumor agent-78 / 否
HY-151429 Antitumor agent-77 / 否
HY-151443 HDAC-IN-47 Inhibitor / 否
HY-153494 Rosomidnar Inhibitor / 否
HY-153494A Rosomidnar sodium Inhibitor / 否
HY-153953 Bcl-2-IN-11 Inhibitor / 否
HY-155242 VEGFR-2-IN-36 / 否
HY-156096 HDAC3-IN-2 / 否
HY-156877 Bcl-2-IN-16 / 否
HY-157343 GD3 Ganglioside / 否
HY-157343A GD3 Ganglioside sodium ≥98.0% 否
HY-159513 Bcl-2/Mcl-1-IN-4 Inhibitor / 否
HY-159668 DL002 / 否
HY-159817 Asaretoclax Inhibitor / 否
HY-160108 Bcl-2-IN-17 Inhibitor / 否
HY-161415 BCL-xL/BCL-2 ligand 1 / 否
HY-161577 BFC1103 / 否
HY-161659 Apoptosis inducer 19 / 否
HY-161732 GQN-B37-E Inhibitor / 否
HY-161786 Bcl-2-IN-20 / 否
HY-162148 HNPMI Inhibitor 99.57% 否
HY-162820 Bcl-2-IN-21 Inhibitor / 否
HY-162826 Apoptosis inducer 27 Inducer / 否
HY-162886 BSO-07 Activator / 否
HY-163077 Anticancer agent 175 Inducer / 否
HY-163308 Bcl-2-IN-18 Inhibitor / 否
HY-163309 Bcl-2-IN-19 Inhibitor / 否
HY-163435 Anticancer agent 201 / 否
HY-163527 FGFR-IN-13 Inhibitor / 否
HY-163764 Bfl-1-IN-4 / 否
HY-167825 Barakol / 否
HY-168171 ERK1/2 inhibitor 11 / 否
HY-168623 EGFR-IN-134 / 否
HY-168739 Topoisomerase I inhibitor 17 / 否
HY-169083 Bcl-2-IN-22 Inhibitor / 否
HY-169096 DPP-21 / 否
HY-169124 Apoptosis inducer 28 / 否
HY-169265 BRD-K20733377 Inhibitor / 否
HY-169266 BRD-K56819078 Inhibitor / 否
HY-169267 BRD-K44839765 Inhibitor / 否
HY-169412 MAPK-IN-3 / 否
HY-169431 VEGFR-2/AKT-IN-2 / 否
HY-170434 Bfl-1-IN-6 / 否
HY-170648 TS-IN-5 / 否
HY-170689 CG-3-246 Inhibitor / 否
HY-18628S UMI-77-d4 Inhibitor / 否
HY-50907S ABT-737-d8 99.11% 否
HY-B0011AS Docetaxel-d5 trihydrate / 否
HY-N0361S Dihydrocapsaicin-d3 / 否
HY-N10091 2,3-Dihydro-3α-methoxynimbolide / 否
HY-N1218 Stellasterol Inhibitor / 否
HY-N1930 (-)-Hinesol Inducer / 否
HY-N2741 Vitexin B-1 Inhibitor / 否
HY-N3828 epi-Eriocalyxin A / 否
HY-P10057 cpm-1285 Inducer / 否
HY-P10058 cpm-1285m / 否
HY-P1889A Bim BH3, Peptide IV TFA / 否
HY-P5324 Bad BH3 (mouse) / 否
HY-P5325 Bid BH3 (80-99) / 否
HY-P5327 r8 Bid BH3 / 否
HY-RS01416 Bcl2 Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01417 BCL2 Rat Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01418 BCL2A1 Human Pre-designed siRNA Set A / 否
HY-RS01419 Bcl2a1 Rat Pre-designed siRNA Set A / 否
HY-RS01420 Bcl2a1a Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01421 BCL2L1 Human Pre-designed siRNA Set A / 否
HY-RS01422 Bcl2l1 Mouse Pre-designed siRNA Set A / 否
HY-RS01423 Bcl2l1 Rat Pre-designed siRNA Set A / 否
HY-RS01424 BCL2L10 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01425 Bcl2l10 Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01426 Bcl2l10 Rat Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01427 BCL2L11 Human Pre-designed siRNA Set A / 否
HY-RS01428 Bcl2l11 Mouse Pre-designed siRNA Set A / 否
HY-RS01429 Bcl2l11 Rat Pre-designed siRNA Set A / 否
HY-RS01430 BCL2L12 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01432 BCL2L14 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01433 BCL2L15 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01434 BCL2L2 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01435 Bcl2l2 Mouse Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01436 Bcl2l2 Rat Pre-designed siRNA Set A Pre-designed Sets / 否
HY-101083A (Rac)-BDA-366 Inhibitor / 否
HY-111244 DCB-3503 / 否
HY-115529 (-)BI97D6 Inducer / 否
HY-116204 SKLB70326 / 否
HY-116532 YCW-E11 Inhibitor / 否
HY-117136 AN-7 / 否
HY-12011A (Rac)-HA14-1 Inhibitor / 否
HY-122047 SW063058 / 否
HY-123715 Anticancer agent 255 / 否
HY-127057 Lambertianic acid / 否
HY-136714 Bcl-2-IN-3 Inhibitor / 否
HY-164468 Ch282-5 Inhibitor / 否
HY-167881 MLS-0053105 Inhibitor / 否
HY-171031 TFGF-18 / 否
HY-N15136 Isomorellinol Inducer / 否
HY-N8579 Eugenyl benzoate / 否
HY-P10336 Serpinin Agonist / 否
HY-W751400 Solasodine hydrochloride / 否
HY-18106 BM 957 Inhibitor / 否
HY-P1733 BMf-BH3 / 否
抗体抑制剂 (1)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P990344 Anti-Bcl-2 Antibody Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens BCL2 NCBI NCBI:596
Mus musculus BCL2 NCBI NCBI:12043
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z